Acetaminophen Protects Against Iron-Induced Cardiac Damage in Gerbils by Walker, Ernest M., Jr. et al.
Marshall University
Marshall Digital Scholar
Faculty Research Marshall Institute for Interdisciplinary Research
1-1-2007
Acetaminophen Protects Against Iron-Induced
Cardiac Damage in Gerbils
Ernest M. Walker Jr.
Marshall University
Christopher P. Epling
Marshall University
Cordel Parris
Marshall University
Silvestre Cansino
Marshall University, cansino@marshall.edu
Protip Ghosh
Marshall University
See next page for additional authors
Follow this and additional works at: http://mds.marshall.edu/miir_faculty
Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, and the
Cardiovascular Diseases Commons
This Article is brought to you for free and open access by the Marshall Institute for Interdisciplinary Research at Marshall Digital Scholar. It has been
accepted for inclusion in Faculty Research by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu.
Recommended Citation
Walker, Ernest M., et al. "Acetaminophen protects against iron-induced cardiac damage in gerbils." Annals of Clinical & Laboratory
Science, 37.1 (2007): 22-33.
Authors
Ernest M. Walker Jr., Christopher P. Epling, Cordel Parris, Silvestre Cansino, Protip Ghosh, Devashish H.
Desai, Ryan G. Morrison, Gary L. Wright, Paulette Wehner, Elsa I. Mangiarua, Sandra M. Walker, and Eric R.
Blough
This article is available at Marshall Digital Scholar: http://mds.marshall.edu/miir_faculty/14
Acetaminophen Protects Against Iron-Induced 
Cardiac Damage in Gerbils
Ernest M. Walker, Jr.,1,2 Christopher P. Epling,2 Cordel Parris,2 Silvestre Cansino,2 Protip Ghosh,3 
Devashish H. Desai,4 Ryan G. Morrison,4 Gary L. Wright,4 Paulette Wehner,2 Elsa I. Mangiarua,4 
Sandra M. Walker,5 and Eric R. Blough6 
1 Pathology, 2 Cardiovascular Services, 3 Geology, 4 Physiology,,and 6 Biology Departments, Marshall 
University; 5 Marshall  Community & Technical College and St Mary’s Medical Center, Huntington, 
WestVirginia
Abstract. Th ere are few eff ective agents that safely remove excess iron from iron-overloaded individuals. 
Our goal was to evaluate the iron-removing eff ectiveness of acetaminophen given ip or orally in the gerbil 
iron-overload model. Male gerbils were divided into 5 groups: saline controls, iron-overloaded controls, 
iron-overloaded treated with ip acetaminophen, iron-overloaded treated with oral acetaminophen, and 
iron-overloaded treated with ip deferoxamine.  Iron dextran was injected ip twice/wk for 8 wk. Acetaminophen 
and deferoxamine treatments were given on Mondays, Wednesdays, and Fridays during the same 8 wk and 
continued for 4 wk after completion of iron-overloading. Echocardiograms were performed after completion 
of the iron-overloading and drug treatments.  Liver and cardiac iron contents were determined by inductively 
coupled plasma atomic emission spectrometry (ICP-AES).  Iron-overloaded controls had 232-fold and 16-
fold increases in liver and cardiac iron content, respectively, compared to saline controls. In iron-overloaded 
controls, echocardiography showed cardiac hypertrophy, right and left ventricular distension, signifi cant 
reduction in left ventricular ejection fraction (-22%), and fractional shortening (-31%) during systole. 
Treatments with acetaminophen (ip or oral) or deferoxamine (ip) were equally eff ective in reducing cardiac 
iron content and in preventing cardiac structural and functional changes.  Both agents also signifi cantly 
reduced excess hepatic iron content, although acetaminophen was less eff ective than deferoxamine.  Th e 
results suggest that acetaminophen may be useful for treatment of iron-induced pathology.
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Introduction
It is estimated that >2 million persons in the United 
States and up to 100 million persons worldwide 
acquire some degree of iron-overload [1].  Th ere are 
2 major causes of iron-overload in humans. Th e 
fi rst is transfusional iron-overload, resulting from 
frequent blood transfusions in patients with thalas-
semia, sickle cell disease, or myelodysplastic synd-
rome. Th e second is hereditary hemochromatosis, 
an autosomal recessive disorder with a frequency of 
about 10% in persons of European descent [2-4]. 
While only 0.5% of subjects are homozygous for 
this trait, nearly 40 million people worldwide have 
iron-overload due to hereditary hemochromatosis 
and various types of hemosiderosis.  In these cases, 
tissue iron levels progressively increase with age 
and may cause life-threatening complications. 
Th ese  include advanced liver disease and cirrhosis, 
diabetes mellitus likely due to accumulation of iron 
in pancreatic islets with direct damage to beta cells, 
and cardiotoxicity due to accumulation of iron in 
myocytes and interstitial cells of the myocardium, 
and within the fi bers of the conduction system. 
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 Cardiomyopathy from excess cardiac iron is 
the major cause of death in thalassemia patients 
[5,6].  Excess iron accumulation in the heart may 
cause cardiac hypertrophy, dilatation, myocardial 
fi ber degeneration, and fi brosis [7].  Th e survival of 
patients with beta thalassemia and sickle cell 
anemia is determined by the magnitude of cardiac 
iron-loading [8].  Removal of excess iron is necessary 
to improve morbidity and reduce mortality of 
patients with thalassemia and sickle cell disease [7]. 
Cardiotoxic eff ects may be severe, with cellular 
degeneration and fi brosis of the myocardium, 
disturbances of cardiac rhythm, and eventual 
death.  However, even individuals with only mild 
to moderate elevations of tissue iron appear to have 
increased risk for diabetes mellitus, heart disease, 
G-I cancers, and hematological malignancies [1].
 Treatment with phlebotomy results in some 
clinical improvement of subjects with elevations in 
tissue iron burden and, if used as preventive therapy, 
may ameliorate organ damage and result in normal 
life expectancy [9]. However, this treatment requires 
repeated removal of up to a liter of blood for periods 
of a year or longer, followed by lifetime maintenance 
phlebotomy. Chelation therapy with currently 
approved chelating agents is a poor substitute for 
phlebotomy and is used mainly in treating patients 
with secondary hemochromatosis or hemosiderosis. 
Th ere are currently 3 iron chelators in clinical use 
or in late-stage development; these are Desferal 
(deferoxamine), deferiprone (L1), and Exjade 
(deferasirox, ICL670) [6].
 Desferal (deferoxamine). Th e major chelator 
agent approved for iron removal in humans is 
deferoxamine, which may be benefi cial as a cardio-
protective agent through its ability to remove excess 
iron and possibly to act as an antioxidant. 
Deferoxamine has demonstrated effi  cacy in 
removing excess iron, preventing early death, and 
improving survival rates in thalassemia patients 
[6,10,11].  Deferoxamine must be administered by 
iv, sc, or im routes and is ineff ective when given 
orally.  It can be associated with side eff ects such as 
visual and auditory disturbances, urticaria, hypo-
tension, poor patient tolerance, and low compliance 
[6,7,8,12,13]. Deferoxamine is a hexadentate 
chelator that combines with iron at a 1:1 ratio to 
form a stable inert complex [14].
 Deferiprone (L1).  Deferiprone is approved as a 
second-line therapy for patients unable to receive 
deferoxamine or in whom deferoxamine is less 
eff ective [6].  Deferiprone is eff ective orally, but has 
a short half-life so that multiple daily oral doses are 
required. It is associated with serious toxic side 
eff ects in some recipients, including increase of 
serum transaminase activity, joint problems, 
neutropenia, and agranulocytosis [6,8,14].  Th ere is 
a risk of paradoxical aggravation of iron toxicity by 
deferiprone [14].  Liver iron levels and body burdens 
of iron may not be as well controlled for long 
periods (4-6 yr) with deferiprone vs deferoxamine 
and may remain at levels above the threshold 
associated with heart disease in 18% to 65% of 
patients [8,15-20]. Benefi cial eff ects of deferiprone 
on heart disease are unclear and appear to be 
improved when the agent is given in combination 
with deferoxamine [8,21].  Th ree molecules of 
deferiprone are required to bind one molecule of 
iron [6,8]. Th e use of deferiprone may produce zinc 
defi ciency in some patients [6].
 Exjade (deferasirox, ICL670, Novartis). 
Deferasirox has recently been evaluated in phase 
IIb/III studies and approved for clinical use.  It has 
a long half-life so that it can be used for once-daily 
dosing [6,22,23].  Early clinical results suggest that 
reasonable doses of deferasirox eff ectively control 
excess iron levels and that deferasirox has equivalent 
effi  cacy to deferoxamine [6]. Deferasirox also shows 
high effi  cacy and therapeutic safety in preclinical 
animal studies [8,24,25]. Two molecules of 
deferasirox bind one molecule of ferric iron [6].
 Th ere is a great clinical need for an orally active 
iron-chelating drug for treating cases of iron-
overload.  Based on earlier work by our laboratory 
[26], we tested the eff ectiveness of acetaminophen, 
given ip or orally, for the reduction of tissue iron 
levels and prevention of cardiopathology in the 
Mongolian golden gerbil iron-overload model. 
 
Materials and Methods
Animals.  Twelve-wk-old male pathogen-free Mongolian 
golden gerbils (Hilltop Laboratories, Scottsdale, PA) were 
housed on wood chip bedding in plastic cages in rooms kept 
at 23 ± 2°C with a 12 hr light/dark cycle.  Purina gerbil mix 
and tap water were available ad libitum.  All animal procedures 
were approved by the Marshall University Institutional 
Animal Care and Use Committee.
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Treatments.  Animals (average wt 60 g) were divided into 5 
groups (16 gerbils/group). (SC)saline control gerbils received 
ip injection of 1% saline (0.15 ml/kg) twice/wk for 8 wk. (IO) 
iron-overloaded control  animals were subjected to a similar 
schedule of twice/wk ip injections of iron dextran (120 mg/
kg, ferric hydroxide dextran complex, Sigma Chemical Co., 
St. Louis, MO) dissolved in 1% saline. (IOAi) acetaminophen-
injected animals received ip injections of iron dextran twice/
wk and acetaminophen (150 mg/kg or 1.0 mM/kg, 4-
acetaminophen, Sigma) 3 times/wk (Monday, Wednesday, 
Friday).  Acetaminophen was injected 4 hr after the iron 
injection when both were given on the same days. Th e 
acetaminophen treatment was continued 3 times/wk (M,W,F) 
for 4 wk after the completion of iron-overloading.  (IOAo) 
these animals, which received oral acetaminophen, were given 
ip iron dextran twice/weekly and acetaminophen (150 mg/kg 
in saline) by gavage 3 times/wk (M,W,F) for the fi rst 9 
treatments.  Animal distress due to repeated gavages forced 
additional oral acetaminophen to be given in drinking water 
at an initial acetaminophen concentration of about 1.2 mg/
ml. Water intake was monitored and averaged 5 ml/gerbil/
day. Animals were periodically weighed and the acetaminophen 
concentration adjusted as necessary to regulate the oral dosage 
(approximately 100 mg/kg/day). Oral acetaminophen treat-
ment was continued for 4 wk after completion of iron-
overloading.  (IODF) this group of gerbils received ip iron 
dextran twice/wk and deferoxamine (IODF) 3 times/wk. 
Deferoxamine in the form of the methanesulfonate salt (82 
mg/kg or 0.125 mM/kg, Sigma) was administered about 4 hr 
after the iron injection when both were given on the same 
days.  Deferoxamine treatment was continued 3 times/wk for 
4 wk after the completion of iron-overloading, so that the 
total period of treatment and observation was 12 wk. ECHO 
studies were conducted on all gerbils 8 wk after completion of 
treatment and the gerbils were killed at 20-21 wk into the 
experiment for histopathologic studies and measurements of 
cardiac and hepatic iron contents. Th e disposition of gerbils 
in the 5 experimental groups is listed in Table 1.
ECHO studies.  ECHO cardiac structural and functional 
values have not previously been reported for gerbils.  Groups 
of control gerbils (n = 16) and iron-overloaded gerbils (n = 16 
less one death, or n = 15) were studied to ensure the validity 
and statistical power of the results.  Nine of 16 iron-overloaded, 
acetaminophen-injected (IOAi), 10 of 16 iron-overloaded, 
acetaminophen orally administered, and 7 of 16 iron-
overloaded, deferoxamine injected animals were randomly 
selected for ECHO studies. One IOAi gerbil died during 
ECHO studies and 6 IOAi gerbils were used for non-ECHO 
studies.  Six IOAo gerbils were used for non-ECHO studies. 
Th ree IODF gerbils died prior to, during, or just after ECHO 
studies and 6 were used for non-ECHO studies. 
 Echocardiography is a noninvasive ultrasound procedure 
in which harmless, high-frequency sound waves (frequency 
>20,000 cycles/sec) are emitted from a piezoelectric crystal or 
transducer, beamed in particular directions, and refl ected 
back (echo) by small structures in the mm and sub-mm range 
[27].  Th ese waves are beamed toward and penetrate the heart 
and are refl ected back to the transducer as a series of echoes, 
which are amplifi ed and displayed on a cathode ray tube [28]. 
Echocardiography is used to evaluate the position, size, and 
movement of cardiac valves, heart wall structure and function, 
and directional fl ow of blood within cardiac chambers [29].   
 Echocardiographic measurements were done with a 
Phillips Sonos 5500 echocardiogram using a S12 transducer 
(frequency range 8-12 MHz). Animals were anesthetized with 
ip injections of a 2:1 mixture of ketamine HCl (100 mg/ml) 
and xylazine (20 mg/ml) (approximately 0.3 to 0.4 ml/100 g 
gerbil wt). Gerbils were shaved in the chest area for adequate 
sonic transference, an ultrasonic transmission gel was applied 
to the chest area, and the animals were positioned on their left 
sides or backs. Echocardiographic images were obtained 
including two-dimensional, pulse wave Doppler and M-mode 
images. Two-dimensional echocardiography was used to 
image the cardiac structures in both the substernal long axis 
and short axis views.  Th ese echocardiographic views were 
then used to position the M-mode echocardiographic line.  In 
the long axis, the probe was oriented toward the base of the 
heart projecting toward the apex (x-axis) with depth along the 
y-axis, thus allowing pulse wave Doppler evaluation of 
valvular blood fl ow velocities.  In short axis procedures, the 
probe was oriented toward the left ventricle and across the 
heart for evaluation of wall structure, which was used in the 
calculation of ejection fraction and fractional shortening 
during systole.  M-mode displays were analyzed by a digital 
echocardiographic analysis system.  Six measurements were 
selected for each assessment of cardiac structure and function. 
Structural parameters included: diastolic (IVSd) and systolic 
(IVSs) left ventricular septal thickness, diastolic (LVIDd) and 
systolic (LVIDs) left ventricular internal dimension, diastolic 
(LVPWd) and systolic (LVPWs) left ventricular posterior wall 
thickness, and right ventricular diastolic internal dimension 
Table 1.  Disposition of gerbils in the 5 experimental groups.
           
Experimental group   Mortality     ECHO studies     Used for histology     Analyzed for iron
Saline controls (SC) (n = 16) 0 16 6 10  
Iron-overload controls (IO)  (n = 16) 3 15 6 10*
Iron-overload acetaminophen ip (IOAi) (n = 16) 1 9 6 9   
Iron-overload acetaminophen po (IOAo)  (n = 16) 0 10 6 10
Iron-overload deferoxamine ip (IODF)  (n = 16) 3  7 6 7
*Th ree iron-overloaded animals died during or after ECHO procedures and their hearts and livers were salvaged for determination 
of iron content.  Th ere were no statistically signifi cant diff erences among the groups regarding mortality.
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(RV).  Functional measurements included: ejection fraction 
(EF), left ventricular fractional shortening during systole 
(FS), maximal aortic (AVmax), pulmonary (PVmax), mitral 
(MVmax), and tricuspid (TVmax) valvular blood fl ow 
velocities.  In addition to direct measurements of cardiac 
mass, echocardiographic measurements were utilized to 
estimate left ventricular mass (LVM) as previously described 
[30]: LVM = 1.04 (LVIDd + IVSd + PWd)3- (LVId)3. 
 Th e wavelength of an ultrasonic pulse is calculated using 
the formula λ = V/F = velocity of pulse in tissue/frequency of 
pulse.  Pulse velocity in tissue is approximately 1,500 m/sec 
[28-30], so λ = 0.125 mm with a 12 MHz transducer.  ECHO 
resolution is the smallest distance between 2 points at which 
the points can be distinguished as separate [28].  Resolution = 
wavelength times pulse length, and the pulse length was 1 
sec.  Th erefore, we were able to accurately measure cardiac 
wall thicknesses of approximately 0.125 mm or greater.
 Sensitivity is the ability of a system to image small targets 
located at specifi c depths in an attenuative medium [28].  It is 
determined by the transducer transmitting effi  ciency times 
the transducer receiving effi  ciency of the refl ected pulse 
(echo).  System effi  ciency is infl uenced by transducer beam 
geometry, frequency spectrum, and energy conversion 
effi  ciency.  Th e typical transducer used in ECHOs of adult 
patients is about 2.25-MHz and has an effi  ciency of about 
4.4% [28].  3.5-MHz transducers are typically used in younger 
children and 5-MHz transducers in infants and neonates.  In 
the gerbils, a 12-MHz transducer was used and the beam 
traveled a much shorter distance to detect gerbil hearts, 
compared to human hearts, so that the system effi  ciency 
should be considerably greater.
Liver and cardiac iron content.  After completion of the 
echocardiographs (12-13 wk), the gerbils were euthanized by 
exsanguination via cardiac puncture or by carbon dioxide 
inhalation.  Hearts and livers were removed by dissection, 
weighed to the nearest mg, frozen in liquid nitrogen, and 
stored at -70°C until analysis.  Whole hearts and liver samples 
were digested in concentrated nitric and perchloric acids 
(70:30, v/v).  Iron concentration was determined in tissue 
digestates by inductively coupled plasma-atomic emission 
spectrometry (ICP-AES) [31]. 
Histological techniques. Animals from each group were killed 
after completion of treatment and ECHO procedures.  Six 
animals were histologically evaluated from each group. Whole 
hearts (breadloaf sectioned) and representative sections of 
liver, spleen, pancreas, and testes were fi xed in 10% buff ered 
formalin solution and processed into paraffi  n blocks by 
routine procedures. Representative 3-5 μm slices were cut 
with a cryostat and sections were mounted on glass slides for 
staining with hematoxylin and eosin (H & E), Perls iron 
stain, or Mallory trichrome stain. Bone marrow samples were 
obtained from cross-section blocks of gerbil spinal column 
and from femurs and were fi xed in B-5 solution after light 
decalcifi cation, processed, sections cut and mounted on glass 
slides, and stained with H & E or Perls iron stain.  Slides were 
evaluated by light microscopy.
Studies in vitro.  Five ml of acetaminophen (10-3 M, clear 
solution) was added to 5 ml of Fe(II)SO4•7H2O (10-3 M, 
clear solution) or Fe(III)Cl3•6H2O (10-3 M, light yellow 
solution) in glass scintillation vials that were capped, shaken 
periodically, and observed at 23°C for up to 48 hr.    
Table 2.   Echocardiographic evaluation of cardiac structural parameters in the experimental groups of gerbils.
Group N IVSd (cm) IVSs (cm) LVIDd (cm) LVIDs (cm) LVPWd (cm) LVPWs (cm) RV (cm)
SC 16 0.09 ± 0.01 0.15 ± 0.01 0.43 ± 0.01 0.27 ± 0.01 0.11 ± 0.01 0.14 ± 0.01 0.14 ±0.01
IO 15 0.13 ± 0.01* 0.19 ± 0.01* 0.53 ± 0.02* 0.35 ± 0.01* 0.17 ± 0.01* 0.19 ± 0.01* 0.20 ± 0.01*
IOAi 9 0.09 ± 0.01+ 0.14 ± 0.01+ 0.44 ± 0.01+ 0.30 ± 0.01*+ 0.11 ±  0.01+ 0.15 ± 0.01+ 0.12 ± 0.01+
IOAo 10 0.09 ± 0.02+ 0.15 ± 0.02+ 0.48 ± 0.02+ 0.31 ± 0.02*+ 0.10 ± 0.01+ 0.16 ± 0.02+ 0.12 ± 0.02+
IODF 7 0.10 ± 0.01+ 0.15 ± 0.01+ 0.43 ± 0.02+ 0.27 ± 0.01+ 0.12 ± 0.01+ 0.15 ± 0.01+ 0.14 ± 0.01+
An asterisk (*) or cross (+) indicates signifi cant diff erence (p < 0.05) from saline control (SC) and iron-overload (IO) groups, 
respectively. See Materials and Methods for abbreviations.
Table 3. Echocardiographic evaluation of cardiac functional parameters in the experimental groups of gerbils.
Group EF (%) FS %) AV Max (cm/sec) PV Max (cm/sec) MV Max (cm/sec) TV Max (cm/sec)
SC 77.5 ± 1.5 40.4 ± 1.5 47.2 ± 2.5 48.9 ± 3.2 41.0 ± 3.9  40.3 ± 2.6
IO 60.6 ± 1.8* 27.9 ± 1.3* 49.8 ±2.4 52.9 ± 4.2 38.0 ± 3.7 38.1 ± 3.1
IOAi 72.5 ± 1.7*+ 35.0 ± 2.0*+  70.4 ± 4.0*+   66.2 ± 4.4*+   50.7 ± 2.9*+    51.0 ± 4.0*+
IOAo 76.4 ± 1.7+ 39.3 ± 1.3+ 58.6 ± 3.3*,+ 58.1 ± 4.0* 44.3 ± 3.4 37.0 ± 1.8
IODF 67.1 ± 1.1*,+ 34.1 ± 2.4*,+ 53.4 ± 3.9 47.6 ± 3.2 39.8 ± 3.2 37.6 ± 2.3
An asterisk (*) or cross (+) indicates signifi cant diff erence (p < 0.05) from saline control (SC) and iron-overload (IO) groups, 
respectively.  See Materials and Methods for abbreviations.
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Statistics.  Data were expressed as means ± SD.  Statistical 
analyses were performed using Sigma Stat statistical software 
(Jandel Corporation, San Rafael, CA).  Diff erences among 
groups were assessed by 2-way ANOVA, followed by Tukey 
test. Values of p ≤ 0.05 were deemed statistically signifi cant.
Results
Cardiac structure and function.  Iron overloading 
resulted in signifi cant increases in left ventricular 
septal (IVSd, IVSs) and posterior wall (LVPWd, 
LVPWs) thicknesses as well as left (LVIDd, LVIDs) 
and right ventricular (RV) internal dimensions 
(Table 2).  Treatments with either acetaminophen 
or deferoxamine by ip injection were equally 
eff ective in preventing iron overloading-induced 
changes in cardiac structure.  Oral administration 
of acetaminophen also prevented iron-induced 
changes; the decreases in left ventricular dimensions 
(LVIDd, LVIDs) were statistically diff erent from 
the values obtained in IO animals.
 Iron-overloading resulted in signifi cant 
decreases in the ejection fraction (-22%) and left 
ventricular fractional shortening during systole (-
31%), with little or no change in valvular blood 
fl ow velocities (Table 3).  Both oral administration 
and ip injection of acetaminophen prevented these 
losses in function.  Deferoxamine ip signifi cantly 
prevented or reversed iron-induced decreases in 
ejection fraction and left ventricular fractional 
shortening (FS) during systole. Th e ip injections of 
acetaminophen caused a signifi cant increase in 
maximal aortic (AVmax), pulmonary (PVmax), 
and tricuspid (TVmax) valvular blood fl ow velocity, 
suggesting a positive inotropic eff ect of the drug.
Tissue iron evaluation.  Iron overloading resulted 
in 232-fold increase in liver and 16-fold increase in 
cardiac iron content (Fig. 1). Treatments with either 
acetaminophen (ip, oral) or deferoxamine (ip) were 
roughly equal in partially reducing the cardiac iron 
burden in iron-overloaded animals. Average post-
treatment cardiac iron concentrations were: SC, 
15.11 ± 11.77 ug; IO, 243.36 ± 51.08 ug; IOAi, 
130.38 ± 29.58 ug; IOAo, 133.76 ± 27.95 ug; IODF, 
110.50 ± 7.47 ug (p values IOAi vs IOAo or DF 
>0.05; IOAo vs DF >0.05).  As shown in Fig. 1, 
acetaminophen (ip, oral) appeared less eff ective 
than deferoxamine (ip) in reducing hepatic 
concentrations of excess iron. Average post-
treatment hepatic iron concentrations were:  SC, 
0.201 ± 0.016 mg; IO, 46.623 ± 1.457 mg; IOAi, 
33.139 ± 6.780 mg; IOAo, 33.516 ± 6.812 mg; 
IODF, 19.567 ± 1.636 mg (p values IOAi vs IOAo 
>0.05; IOAi or IOAo vs DF <0.05).  
 Iron accumulation was noted in most gerbil 
tissues with the least in the central nervous system. 
In iron-overloaded gerbils, hemosiderin iron 
deposition was seen in gerbil liver (Fig. 3A), 
pancreas (Fig. 3B), spleen (Fig. 3D), myocardial 
cells and interstitial spaces (Fig. 2A,C), aorta (Fig. 
2D,E), kidney (Fig. 3C), pituitary, thyroid, bone 
marrow, and testes. Th e cardiovascular system 
demonstrated iron accumulation in myocardial 
cells, and interstitial spaces (Fig. 2A,C), while the 
aortas accumulated iron in all vascular layers, most 
marked in tunica adventitias and tunica intimas 
Fig. 1. Hepatic and cardiac iron content of gerbils in the 
experimental groups.  Th e iron content of liver (A) and heart 
(B) of saline controls (SC, n = 10), iron-overloaded (IO, n = 
10), acetaminophen-injected (IOAi, n = 9), acetaminophen 
administered by oral gavage (IOAo, n = 10), and deferoxamine-
injected gerbils (IODF, n = 7).  
An * or + indicates a signifi cant diff erence (p <0.05) from the 
controls or iron-overloaded gerbils, respectively.
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(Fig. 2D,E).  Sections of left ventricle from iron-
overloaded gerbils showed areas of iron-induced 
destruction and necrosis of cardiac muscle (Fig. 
2B).  Liver sections stained with iron stain (Prussian 
blue) demonstrated accumulation of hemosiderin 
iron granules in cytoplasm of hepatocytes, most 
marked in periportal areas (Fig. 3A) and often 
perinuclear in location (arrow). Pancreases were 
intensely pigmented with hemosiderin accumulation 
in acinar and islet cells (Fig. 3B).  Renal sections 
revealed tubular and glomerular accumulations of 
hemosiderin granules (Fig. 3C). Spleens showed 
marked hemosiderin accumulation in both red and 
white pulp (Fig. 3D). Hemosiderin granules accum-
ulated in sections of bone marrow (not shown). 
Testes accumulated iron chiefl y in interstitial spaces 
among seminiferous tubules, but little within 
tubules (not shown).  Hemosiderin iron accumulated 
in the adrenal and thyroid glands (not shown). 
Both acetaminophen (ip or oral) and deferoxamine 
(ip) produced substantial iron reductions in the 
tissues (liver, heart, aorta, spleen, pancreas, bone 
marrow, testis, adrenal, and thyroid), with the least 
reduction in liver and spleen, as judged from 
histological evaluations. Th e body weights of iron-
overloaded gerbils were similar to saline controls, 
indicating that the injections of iron dextran did 
not result in debilitation and weight loss (Table 4). 
By comparison, liver and cardiac weights were 
increased 40% and 43%, respectively, in the IO 
group. Consistent with echocardiographic evidence 
of hypertrophy and increase in heart weight, 
calculation of left ventricular mass indicated an 
approximate increase of 130% in the left ventricular 
mass of iron overloaded animals compared to 
controls (Table 5).  Acetaminophen (ip, oral) and 
deferoxamine (ip) appeared equally eff ective in 
reducing the increases in liver and cardiac weights 
(Tables 4 and 5).
Mortality and arrhythmias. During the total 
period of observation, of 16 saline control (SC) 
gerbils, 0 developed cardiac arrhythmias (ECHO 
studies) and there were 0 deaths. Of 16 iron-
overloaded (IO) gerbils, 9 developed signifi cant 
cardiac arrhythmias, chiefl y premature ventricular 
contractions (PVCs), and 3 of the 9 gerbils died 
after completion of ECHOs and prior to the end of 
the experiments. Th e 16 iron-overloaded gerbils 
treated by acetaminophen ip (IOAi) showed 0 
cardiac arrhythmias and 1 death. Th e 16 iron-
overloaded gerbils treated orally with acetaminophen 
(IOAo) demonstrated 1 animal with cardiac 
arrhythmia (PVCs) and 0 deaths.  Th e 16 iron-
overloaded gerbils treated with deferoxamine ip 
showed 3 animals with cardiac arrhythmias (PVCs), 
which died prior to the end of the experiment.
 
Table 4.  Body, liver, and heart weights of gerbils in the experimental groups.
Group Body wt (g) Liver per body wt (%) Heart per body wt (%)
SC 83.7 ± 2.2 4.10 ± 0.06 0.31 ± 0.01
IO 80.5 ± 2.6 5.78 ± 0.32* 0.46 ± 0.01*
IOAi 85.3 ± 2.4 4.93 ± 0.13*+ 0.40 ± 0.01*+
IOAo 84.2 ± 2.3 5.14 ± 0.20*+ 0.40 ± 0.01*+
IODF 92.6 ± 5.6 4.94 ± 0.11*+ 0.37 ± 0.01*+
An asterisk (*) or cross (+) indicates a signifi cant diff erence (p < 0.05) from saline control (SC) and iron overload (IO) groups, 
respectively.  See Materials and Methods for abbreviations.
Table 5. Left ventricular mass calculated from echo-
cardiographic analysis of gerbils in the control (SC), iron 
overloaded (IO), acetaminophen treatment by ip injection 
(IOAi), acetaminophen treatment by gavage (IOAo), and 
deferoxamine treatment by ip injection (IODF) groups.
Group N LVM (g)
SC 16 0.177 ± 0.005
IO 15 0.408 ± 0.13*
IOAi 9 0.189 ± .007+
IOAo 10 0.205 ± .006*+
IODF 7 0.222 ± .017*+
An asterisk (*) or cross (+) indicates a signifi cant diff erence (p 
<0.05) from the groups of control (SC) or iron-overloaded 
(IO) gerbils, respectively.
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In vitro study.  Acetaminophen reacted in vitro 
with Fe(II)SO4•7H2O (ferrous) (10-3 M, clear 
solution) to produce a brown precipitate and with 
Fe(III)Cl3•6H2O (ferric) (10-3 M, light yellow 
solution ) to yield a rusty-appearing solution, which 
gradually turned dark brown and formed a brown-
black precipitate.  Th ese observations suggest that 
acetaminophen can bind to iron in vitro. 
Discussion
Th e results of this study suggest that acetaminophen 
is equally eff ective as deferoxamine in cardiac iron 
removal and the prevention or reversal of cardiac 
functional and structural abnormalities in the iron-
overloaded gerbil model. ECHO and radionuclide 
ventriculography are the most useful noninvasive 
diagnostic techniques to detect iron-overload-
induced cardiomyopathy [32].  Our ECHO studies 
revealed easily discernable diff erences in cardiac 
structure and function between the saline control 
and iron-overloaded groups and between the iron-
overloaded group and the iron-overloaded treated 
groups.  
Iron localization in human hearts. Normally, there 
is no stainable iron within the myocardium [33]. 
In cases of iron-overload, iron-saturated transferrin 
attaches to transferrin receptors on cardiomyocytes 
and iron is released into the cell to be stored as 
hemosiderin-iron [32]. In iron-overloaded human 
patients, excess iron accumulates in cardiomyocytes, 
cardiac macrophages, in cells of the bundle of His 
and Purkinje system, and in interstitial spaces of 
the heart [32].  In cases of hemochromatosis or 
hemosiderosis, iron deposits tend to be more 
extensive in the epicardial third of the ventricle, 
followed by the subendocardium and papillary 
muscle, and least in the middle third of the 
ventricular wall. Hematoxylin and eosin as well as 
Fig. 2. Cardiac (A-C) and aortic (D and E) iron deposits in iron-overloaded gerbils (group IO): 2A depicts iron accumulations 
(blue granules) in cardiac interstitial cells and cardiomyocytes (Perls iron stain, 100X); 2B depicts iron-induced damage and 
necrosis of cardiac muscle (H&E, 100X); 2C shows iron accumulations (blue granules) in cardiac interstitial cells and 
cardiomyocytes (Perls iron stain, 100X); 2D demonstrates iron deposits in all layers of iron-overloaded aortic wall, but especially 
concentrated in the adventitial area (Perls iron stain, 40X); 2E is a higher power view of 2D (Perls iron stain, 400X).
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Prussian blue staining show hypertrophic myocytes 
with hemosiderin iron in perinuclear locations in 
cells, but with increased iron concentrations 
eventually occupying most of the cells and 
occasionally totally replacing myocytes [33].  Iron 
accumulations in the cardiac conduction system, 
coronary arteries, and valves are usually limited, 
but involvement of the conduction system is 
associated with cardiac arrhythmias. Iron accumu-
lation in the bundle of His and Purkinje system 
may impair signal conduction from the atrial pace-
maker to the ventricles and this may result in 
arrhythmias and sudden death [32]. Cardiac fi brosis 
may be present and result in restrictive cardiac 
hemodynamics [33]. Th ere is signifi cant correlation 
between serum ferritin concentrations and the 
endomyocardial biopsy grade.  Patients with high 
ferritin levels and poor compliance to treatment 
Fig. 3.   Liver (A), pancreatic (B), kidney (C), and splenic (D) iron deposits in iron-overloaded gerbils (group IO): 3A reveals iron 
deposits in hepatocytes and Kupff er cells.  Perinuclear iron distribution occurs in hepatocytes (arrow) (Perls iron stain, 40X); 3B 
shows iron distribution in pancreas, emphasizing iron deposits in pancreatic cells, including islet and beta cells (Perls iron stain, 
400X); 3C illustrates iron in kidney (blue granules) including glomerular and tubular iron deposits and tubular damage (Perls 
iron stain, 100X); 3D shows iron distribution (blue granules) in splenic red and white pulp (Perls iron stain, 100X).
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with chelating agents are at high risk of cardiac 
hemochromatosis and its complications [33].  
Iron localization in gerbil hearts and aortas.  Iron 
distribution in the gerbil hearts was almost identical 
to that reported in human hearts. Marked iron 
accumulations were seen in the ventricles, less in 
atria, and little in fi bers of the conduction system, 
valves, or coronary arteries.  Appreciable quantities 
of iron accumulated in gerbil aortas, especially in 
the adventitial region.  Iron accumulations were 
evident in cardiomyocytes, cardiac macrophages, 
and interstitial spaces.  Infi ltrating fi brosis in gerbil 
heart ventricles was similar to that which sometimes 
occurs in hearts of iron-overloaded patients. 
 Hemosiderin iron is innocuous, but it is in 
equilibrium with a small pool of loosely bound 
(“free”) iron in cardiomyocytes.  Loosely bound 
iron is capable of catalyzing the formation of ROS 
(reactive oxygen species) through the Fenton 
reaction. Th e ROS can cause oxidant-mediated 
injury to cells. Cardiac cells are particularly sensitive 
to oxidant-induced damage since they contain a 
high concentration of mitochondria and maintain 
a high degree of metabolic function, which includes 
performing complex operations such as contraction 
and transmission of electrical impulses [32]. By 
binding iron, deferoxamine and acetaminophen 
may reduce or prevent the generation of ROS via 
the Fenton reaction, thus protecting against cellular 
damage and restoring normal cellular activity.  
 Pathogen-free Mongolian gerbils were used in 
this study to avoid the increased morbidity and 
mortality and advanced hepatocellular necrosis 
observed in gerbil strains (eg, Psammomys obesus) 
with coincidental laboratory infections [14]. 
Acetaminophen was as eff ective as deferoxamine in 
reducing cardiac excess iron content and preventing 
echocardiographic evidence of cardiotoxicity in 
iron-overloaded gerbils. Acetaminophen and 
deferoxamine treatments both reduced hepatic 
excess iron content, although acetaminophen was 
less eff ective than deferoxamine. Th is may be due 
to tight binding of iron to the high concentrations 
of ferritin and similar molecules in the liver. 
 Th e gerbil iron-overload model was fi rst 
described by Carthew et al [34] and provides an 
excellent experimental model for the study of iron-
overloading of the heart and liver.  Iron overloading 
in the gerbil model closely simulates the features 
observed in transfusion iron-overloaded patients 
[34].  Weekly injections of iron dextran in gerbils 
result in accumulation of ferritin in perisinusoidal 
cells, Kupff er cells, and hepatocytes with subsequent 
scarring hepatic fi brosis [35] and suppression of 
mitochondrial respiratory enzyme activities [39]. 
Others have shown the development of cardio-
myopathy in the iron-overloaded gerbil [14,37-41]. 
Subepicardial and subendothelial areas and the 
intraventricular septum in gerbil hearts were 
primarily aff ected, as occurs with severe iron 
overload in humans.  Similarly, intracellular iron in 
individual myocytes showed a characteristic 
perinuclear pattern in gerbils, as seen in human 
hemochromatosis.  Within 12 wk from the start of 
iron administration, iron-overload in the gerbil 
resulted in signifi cant increase of cardiac iron 
content with progressive development of hyper-
trophy, electrocardiographic abnormalities, and 
reduced function. Th e similarities of iron accumul-
ation, distribution, and associated pathology in 
gerbil and human hearts and their similar responses 
to iron-removing therapy emphasize the value of 
the Mongolian gerbil iron-overload model in 
studying iron-induced cardiovascular pathology 
and therapeutic interventions.
 Our study showed iron-induced changes in 
cardiac structure and function in the gerbil model 
based on echocardiographic fi ndings. Consistent 
with previous reports, the present results indicate 
cardiac hypertrophy with possible ventricular 
distension (Table 2) and signifi cant reduction in 
function (Table 3). Similar to previous studies 
[14,36,39,41], we found that chelation therapy with 
deferoxamine prevents functional abnormalities in 
the gerbil model.  Furthermore, we demonstrated 
that oral or ip administration of acetaminophen 
partially or totally prevents the changes in structure 
and cardiac function. Acetaminophen and deferox-
amine were equally eff ective in reducing excess 
cardiac iron.  Acetaminophen and deferoxamine 
both reduced the accumulation of iron in livers and 
hearts of iron-overloaded gerbils (Fig. 1). Acet-
aminophen provided signifi cant cardio-protection 
when given either by ip injection or oral gavage.
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Possible mechanisms of action.  Th e mechanism by 
which acetaminophen provides cardioprotection 
against iron-overload is uncertain.  At high doses 
and prolonged use, acetaminophen is a hepatotoxin 
due to its ability to form free radicals and deplete 
glutathione stores [42,43]. Conversely, acetamino-
phen can also be considered an antioxidant due to 
its ability to protect membranes from lipid oxidation 
by scavenging peroxyl radicals and peroxynitrite 
[44]. In addition to its actions against hydroxyl 
radicals and hydrogen peroxide, acetaminophen 
has also been shown to be effi  cacious against 
peroxynitrate [45], myeloperoxidase [46], cyclooxy-
genase [47], and other peroxides [48]. Acetamino-
phen provides cardioprotection to the postischemic, 
reperfused guinea pig myocardium [49,50].  Given 
before or during ischemia-reperfusion periods, 
acetaminophen treatment produced positive 
inotrophic eff ects, lower coronary perfusion 
pressure, lower coronary vascular resistance, 
retention or recovery of a greater percentage of left 
ventricular function, preservation of myofi brillar 
ultrastructure, attenuation of bursts of hydroxyl 
radicals during reperfusion, reduced release of 
creatine kinase during ischemia-reperfusion, 
reduced production of peroxynitrate, attenuation 
of damaging eff ects of peroxynitrate and hydrogen 
peroxide via protein oxidation, and reduced 
perturbations of myocardial electrical stability.  
 In conclusion, increases in ROS (reactive 
oxygen species) may represent the underlying 
mechanism of iron-induced cardiac and tissue 
damage.  Th erefore, the reduction of excess cardiac 
and tissue iron accumulations should combat the 
iron-associated organ and tissue damage.  Previous 
observations suggest that acetaminophen provides 
signifi cant functional and structural cardiac 
protection, probably by its antioxidant properties 
[26].  Th erefore, the antioxidant characteristics of 
acetaminophen might provide cardioprotection 
and prevent tissue or organ damage in a number of 
conditions such as increased iron concentrations, 
which induce the release of free radicals and other 
oxidants [1].  In the present study, it seems likely 
that acetaminophen may have provided cardio-
protection by dual mechanisms: (a) its antioxidant 
eff ects and (b) the removal of excess cardiac iron.
Speculative mechanisms of iron-binding by 
acetaminophen. Possible mechanisms of iron 
removal include (a) direct chelation or complexing 
of acetaminophen with iron (ferrous and ferric?) 
and (b) reaction of ferric iron with [NAPQI•] (N-
acetyl-p-benzoquinoneimine), the hepatic toxic 
metabolite of acetaminophen, to form iron-NAPQI 
complexes. NAPQI normally reacts with sulfhydryl 
groups of glutathione to form a nontoxic complex. 
However, at very high levels, excess NAPQI, not 
detoxifi ed by glutathione, may react with sulfhydryl 
groups of hepatic proteins to form covalent bonds, 
which lead to cellular necrosis and death [51]. If 
iron is capable of reacting with NAPQI to form a 
nontoxic complex, protection may be provided. 
Future areas for study.  Th at acetaminophen is able 
to mobilize excess iron from the heart and other 
organs is a novel observation.  Acetaminophen has 
been used as an analgesic-antipyretic agent for 
many decades, so that much is known about its 
therapeutic and toxic characteristics. Th e demon-
stration that acetaminophen is orally eff ective as an 
iron removing agent is potentially important, since 
there is a shortage of approved oral agents that are 
therapeutically eff ective in iron removal. However, 
knowledge in key areas regarding acetaminophen 
removal of iron is lacking. Th ese areas must be 
investigated to ensure the clinical safety and 
therapeutic effi  cacy of acetaminophen in its iron-
removing role before human clinical trials can be 
recommended.  Th e areas include: (a) mechanisms 
(chelation or complexing) of acetaminophen 
binding to iron and mobilization of excess tissue 
iron, (b) routes of elimination (urinary or biliary) 
of acetaminophen-iron complexes, and (c) studies 
to determine why acetaminophen is less eff ective in 
mobilizing iron from some organs (liver, spleen) 
than others (heart, kidney) and whether acetamino-
phen binding to hepatic iron is associated with 
redistribution of soluble iron chelates.
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